Korro Bio has lined up a fresh lifeline, saying Monday it has secured a private placement expected to raise roughly $85 million, a cash infusion management says will extend the Cambridge RNA-editing company’s runway into the second half of 2028. The deal follows a tough stretch that included disappointing data for lead candidate KRRO-110, which missed projected protein levels last fall, and a deep staff reduction. If the financing closes, Korro says it plans to use the proceeds to push next-generation, GalNAc-delivered candidates forward and move other liver-focused programs toward clinical data.
Oversubscribed private placement
On March 9, Korro disclosed it had entered a subscription agreement to sell 4,501,928 shares of common stock at $11.11 per share and pre-funded warrants for another 3,148,836 shares, a transaction expected to generate gross proceeds of about $85 million upon closing, according to a filing with the SEC. The filing names Venrock Healthcare Capital Partners as the lead investor and notes that, combined with roughly $85.2 million in cash and marketable securities on hand at year-end, the new money should support the company through upcoming clinical inflection points.
Why the AATD program stumbled
Korro’s Phase 1/2a REWRITE study in alpha-1 antitrypsin deficiency showed its therapy could generate functional M-AAT protein in some patients, but it did not boost total AAT to the company’s protective threshold. That shortfall prompted a move away from a lipid nanoparticle delivery approach. Industry coverage and company commentary framed the readout as proof-of-concept for the RNA-editing platform but not enough for a therapeutic effect, a turn that led management to pivot toward GalNAc-conjugated constructs, BioPharma Dive reported.
Layoffs hit Cambridge labs
As part of that strategic reset, Korro cut roughly 34% of its workforce in November after an earlier round of reductions in the spring, cost-cutting moves executives said were designed to stretch cash while the company retooled its delivery and development plans. The layoffs left the outfit leaner and underscored how a single clinical stumble can rattle small biotechs clustered in Cambridge’s life-sciences ecosystem, Fierce Biotech reported.
What the money has to buy
Korro says the new proceeds, together with the approximately $85.2 million it reported on hand at year-end, will fund clinical data generation for programs including KRRO-121 and a GalNAc-conjugated AATD candidate, while extending the corporate runway into the second half of 2028. The company has also nominated KRRO-121, described as a GalNAc-conjugated program designed to lower ammonia via a de novo protein variant, and it plans to pursue a first-in-human filing in the second half of 2026, according to a SEC filing.
Next milestones and market watch
Investors and potential partners will be watching for the closing of the private placement, which Korro says is expected on or about March 10, and for any near-term development-candidate nominations or IND filings that could validate the company’s new GalNAc delivery strategy. Local business coverage of the transaction appeared in the Boston Business Journal, which first flagged the update for the region’s life-sciences community.
